Buffalo, NY, United States of America

Grace Dy

This inventor holds 1 USPTO granted patent. Top assignees: Centro De Inmunologia Molecular, Innovative Immunotherapy Alliance, S.A.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Grace Dy - Innovator in Therapeutic Compositions

Introduction

Grace Dy is an accomplished inventor based in Buffalo, NY (US). She has made significant contributions to the field of therapeutic compositions, particularly in the treatment of tumors of epithelial origin. Her innovative work has led to the development of a patent that showcases her expertise and dedication to advancing medical science.

Latest Patents

Grace Dy holds a patent titled "Use of Therapeutic Compositions for the Treatment of Patients with Tumors of Epithelial Origin." This patent represents her commitment to finding effective treatments for patients suffering from challenging medical conditions. With 1 patent to her name, she has established herself as a notable figure in her field.

Career Highlights

Throughout her career, Grace Dy has worked with various organizations that focus on immunotherapy and molecular biology. Notably, she has been associated with Innovative Immunotherapy Alliance, S.A. and Centro De Inmunologia Molecular. These experiences have enriched her knowledge and skills, allowing her to contribute meaningfully to the scientific community.

Collaborations

Grace Dy has collaborated with Tania Crombet Ramos, a fellow professional in the field. Their partnership has likely fostered innovative ideas and advancements in therapeutic research.

Conclusion

Grace Dy's work in therapeutic compositions exemplifies her dedication to improving patient outcomes through innovative treatments. Her contributions to the field are commendable and reflect her passion for medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…